

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

**Belluscura plc**  
("Belluscura" or the "Company" or "Group")

#### **Notice of AGM**

**LONDON, U.K. AND PLANO, TX, U.S. (2 August 2024).** Belluscura plc (AIM:BELL), announces that the Notice of Annual General Meeting ("AGM"), to be held at 12.00 p.m on Tuesday 27 August 2024, is being posted to shareholders and will shortly be available on the Company's website at: <https://investors.belluscura.com/investors/shareholder-information>.

The Annual Report and Accounts for the year ended 31 December 2023 is available on the Company's website at: <https://www.belluscura.com/financials/annual-and-interim-reports/>

If you wish to submit a proxy vote for this meeting, please submit your vote online at [www.signalshares.com](http://www.signalshares.com). For your vote to be valid please ensure that it is received by no later than 12.00 p.m. on 25 August 2024. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting.

#### **For further information please contact:**

**Belluscura plc**  
Adam Reynolds, Chairman  
Robert Rauker, Chief Executive Officer  
Simon Neicheril, Chief Financial Officer

Tel: +44 (0)20 3128 8100

**SPARK Advisory Partners Limited**  
**Nominated Adviser**  
Neil Baldwin / Jade Bayat

Tel: +44 (0)20 3368 3550

**Dowgate Capital Limited**  
**Broker**  
James Serjeant / Russell Cook

Tel: +44 (0)20 3903 7715

**MHP**  
**Financial PR & Investor Relations**  
Katie Hunt/Matthew Taylor

Tel: +44 (0)20 3128 8100  
email: [Belluscura@mhpgroup.com](mailto:belluscura@mhpgroup.com)

#### **About Belluscura plc ([www.belluscura.com](http://www.belluscura.com))**

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAFZGGRKMDGDZM